LJI team wins $500,000 XPRIZE for COVID-19 screening protocol
LA JOLLA—A team of scientists at La Jolla Institute for Immunology (LJI) has won the XPRIZE Rapid COVID Testing competition.
Leinco Technologies, Inc., and La Jolla Institute for Immunology announce license agreement to develop novel COVID-19 diagnostic tools
In addition to developing the antibodies for use in diagnostic applications based on N protein-specific antibodies, Leinco will make these antibodies commercially available as part of their extensive catalogue of research tools.
Had Covid? You May Need Only One Dose of Vaccine, Study Suggests
People who have already been sick with Covid-19 should still be vaccinated, experts say, but they may experience intense side effects even after one dose.
Coronavirus mutations add urgency to vaccination effort as experts warn of long battle ahead
T cells can mount attacks against many SARS-CoV-2 targets—even on new virus variant
New LJI research gives detailed look at vulnerable sites on the novel coronavirus—beyond the receptor binding domain
A closer look at T cells reveals big differences in mild vs. severe COVID-19 cases
New research highlights the enormous variability in how T cells respond to the deadly virus
Experts torn over changing vaccine doses to speed up lagging rollout
To speed inoculations, the U.S. plans to release all available vaccine doses and open access to anyone over 65. Others suggest straying from recommended doses or intentionally delaying boosters. The best way forward remains uncertain.
The Future of the Coronavirus? An Annoying Childhood Infection
Once immunity is widespread in adults, the virus rampaging across the world will come to resemble the common cold, scientists predict.
COVID-19 immunity could be long term
New findings suggest that immune response to COVID-19 may be long-lasting.